治疗相关死亡率(TRM)评分对接受异基因造血细胞移植的成人急性髓系白血病患者预后的预测价值
该单中心回顾性研究纳入861例接受异基因造血细胞移植的成人急性髓系白血病患者,评估TRM评分对移植后结局的预测能力。TRM评分四分位组间非复发死亡风险呈阶梯式升高,且TRM评分对非复发死亡的预测区分度优于PAM评分和HCT-CI/年龄复合评分。作者认为TRM评分或可用于此类患者的风险分层。
要点
- TRM评分四分位组间3年非复发死亡风险呈阶梯式升高,Q1为9%,Q4为28%。
- TRM评分预测非复发死亡的C统计量为0.661(连续变量)或0.642(按四分位分类)。
- TRM评分对非复发死亡的预测区分度优于PAM评分(0.603)和HCT-CI/年龄复合评分(0.576)。
核心结论
- 移植后结局预测仍具挑战性,但这些发现提示TRM评分或可用于接受异基因造血细胞移植的成人急性髓系白血病患者的风险分层。
研究设计与样本
- 单中心回顾性研究,纳入861例接受异基因造血细胞移植的成人急性髓系白血病患者,评估TRM评分(原用于预测诱导化疗后早期死亡)对移植后结局的预测价值。
主要发现
- 3年非复发死亡风险随TRM评分四分位组升高而阶梯式增加:Q1为9%(95%CI 5-13%),Q4为28%(95%CI 22-34%)。
- 3年复发风险在TRM评分较低组更低:Q1为26%(95%CI 20-32%),Q4为37%(95%CI 30-43%)。
- 3年无复发生存率随TRM评分升高而逐步下降:Q1为66%(95%CI 59-72%),Q4为36%(95%CI 29-42%)。
- 3年总生存率随TRM评分升高而逐步下降:Q1为72%(95%CI 66-78%),Q4为39%(95%CI 33-46%)。
- TRM评分预测非复发死亡的C统计量为0.661(连续变量)或0.642(按四分位分类),优于PAM评分(0.603)和HCT-CI/年龄复合评分(0.576)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is long-standing interest in estimating non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) for AML, but existing tools have limited discriminative capacity. Using single-institution data from 861 adults with AML, we retrospectively examined the Treatment-Related Mortality (TRM) score, originally developed to predict early mortality following induction chemotherapy, as a predictor of post-HCT outcome. NRM risks increased stepwise across the four TRM score quartiles (at 3 years: 9% [95% confidence interval: 5-13%] in Q1 vs. 28% [22-34%] in Q4). The 3-year risk of relapse was lower in patients with lower TRM score (26% [20-32%] in Q1 vs. 37% [30-43%] in Q4). Consequently, relapse-free survival (RFS) and overall survival (OS) estimates progressively decreased (RFS at 3 years: 66% [59-72%] in Q1 vs. 36% [29-42%] in Q4; OS at 3 years: 72% [66-78%] in Q1 vs. 39% [33-46%] in Q4). With a C-statistic of 0.661 (continuous variable) or 0.642 (categorized by quartile), the TRM score predicted NRM better than the Pretransplantation Assessment of Mortality (PAM) score (0.603) or the HCT-CI/age composite score (0.576). While post-HCT outcome prediction remains challenging, these findings suggest that the TRM score may be useful for risk stratification for adults with AML undergoing allogeneic HCT.
引用
- Zarling LC, Othus M, Sandmaier BM, et al. Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2022. PMID: 35440690. doi:10.1038/s41375-022-01574-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。